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In his Foundation series, published in the 1950’s, Isaac 
Asimov imagined Civilization capable of colonizing the 
entire Universe.  This feat is unlikely to occur.   
Strikingly, Asimov referred to a 70-old man as an old 
individual who is unlikely to live much longer.  Thus, in 
literature’s most daring fantasy, the pace of aging could 
not be slowed.  Yet, given the present pace of discovery 
in the aging field, this feat might become a reality 
within our life time, with science surpassing science 




Once August Weismann had divided life into a 
perishable soma and immortal germ line, the soma 
began to be viewed as disposable.  As Weismann wrote 
in 1889, “the perishable and vulnerable nature of the 
soma was the reason why nature made no effort to 
endow this part of the individual with a life of unlimited 
length” (see [1]).  Weismann speculated that somatic 
mortality might give the individual benefits early in life, 
such as “a better performance of their special 
physiological tasks” … or “an additional material and 
energy available for the reproductive cells”.  This quote 
implies two hypotheses.  Each of them initiated a 
separate direction of thought in gerontology.  First, 
mortality can result from benefits at young ages (e.g., 
better performance).  This idea is the root of the 
antagonistic pleiotropy theory later developed by 
Medawar (1952) [2] and Williams (1957) [3].  Second, 
mortality can result from allocation of limited resources 
for reproduction.  This is the root of the allocation of 
resources or disposable soma theory developed by 
Kirkwood [4].  The allocation hypothesis predict that the 
fewer the resources for reproduction, the shorter lifespan.    
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Experimental data were available to distinguish two 
hypotheses as early as 1917.  It was shown that caloric 
restriction (CR) – a reduction in food intake without 
malnutrition -- extends life span and prevents age-
related infertility in rodents [5].  These data were 
initially forgotten, but have now been reproduced 
numerous times.  In 1930’s, McCay and his colleagues 
also found that CR prolongs life span in rodents.  The 
significance of CR is fully appreciated only now, 
knowing that nutrients modulate cellular signal 
transduction pathways that include AMPK, Sirtuins and 
TOR.  But for a long time the effect of CR on longevity 
remained just a phenomenon, albeit an important one.  
Aging remained an unsolved mystery. 
 
In 1950’s, aging began to be understood from an 
evolutionary perspective.  Because organisms tend to 
die from external causes in the wild, the probability of 
survival to old age is low.  Therefore, the force of 
natural selection weakens with age.  Natural selection, 
which is strong early in life, can favor antagonistically 
pleiotropic genes (AP genes), genes that provide 
benefits early in life but are harmful later.  By 1957, it 
was generally accepted that there were genes that are 
beneficial early in life, but cause aging phenotypes at 
older ages.  This idea predicts that the inactivation of 
some genes will extend life span, but at the cost of 
development or reproduction.  The identity of such 
genes remained enigmatic for two reasons.  First, there 
were no technologies to screen for such genes at that 
time.  Second, it was expected that these genes must 
differ among species.  For example, in mammals there 
might be genes responsible for rapid calcification of 
bones that lead to late-life calcification of athero-
sclerotic plaques (an example suggested by Williams).   
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bones or a circulatory system that is susceptible to 
atherosclerosis.  So, aging of C. elegans and other 
simple organisms was expected to be irrelevant to 
human aging.  Because C. elegans has a short (~3 
weeks) life span and is more suitable for genetic screens 
than monkeys, or, needless to say, humans, 
antagonistically pleiotropic genes remained hypo-
thetical.   
 
Instead, research efforts were focused on obtaining 
evidence for the allocation of resources hypothesis.   
Aging was assumed to result from the random 
accumulation of damage, resulting in chaos and an 
increase of entropy that could not be regulated or 
prevented.  In 2006, some investigators declared that the 
problem of aging had been solved [6, 7].  This view 
declared that aging is just deterioration and functional 
decline due to an accumulation of random molecular 
damage from myriad causes, and refractory to 
substantive intervention [6, 7].  
 
But what about antagonistically pleiotropic genes 
predicted in 1950’s?  It was pointed out that “one of the 
problems with this view, though, is that there are, in 
fact, very few clear-cut examples of candidate 




The first successful screens for genes that postponed 
aging began in the mid 1980’s.  Despite common 
opinion that genes that control aging were unlikely to 
exist, Klass performed a mutagenesis screen for long-
lived C. elegans mutants and found candidates [8], one 
of which, age-1, was characterized by Johnson and 
colleagues [9].  In 1993, Kenyon and colleagues, also 
screening for long-lived C. elegans, found that 
mutations in the gene daf-2 increases the longevity of C. 
elegans  hermaphrodites by more than two-fold 
compared to wild type nematodes [10].  Daf-2 was 
already known to regulate formation of the dauer state, 
a developmentally arrested larval form that is induced 
by crowding and starvation.  Kenyon et al. suggested 
that the longevity of the dauer results from a regulated 
life span extension mechanism.  This discovery 
provided entry points into understanding how life span 
can be extended [10].  So Age-1 and Daf-2 appeared to 
be antagonistically pleiotropic (AP) genes.  As pre-
dicted by the AP theory, Age-1 or Daf-2 inactivation 
extends life span, but at the cost of impaired 
development or fertility [9-10].  Subsequent studies 
showed that Age-1 and Daf-2, as well as Daf-16 and 
Daf-18 (mutations in which suppress life span 
extensions caused by Daf-2 and Age-1 mutations) act in 
the same signal transduction pathway [11].  Similar 
genes were soon identified in yeast, Drosophila and 
mammals, thereby establishing the existence of 
universal genes that control aging [12]. Daf-2 encodes 
an insulin receptor family member [13], and Age-1 
encodes a homologue of mammalian PI-3K catalytic 
subunits [14], which transduce the receptor-mediated 
signals.  On the other hand, Daf-18 is homologue of the 
tumor suppressor PTEN [12], which suppress Daf-2 and 
Age-1 signals.   
 
Soon after these discoveries, the yeast chromatin-
associated protein Sir2 (silent information regulator-2) 
and its mammalian ortholog SIRT1, as well as other 
sirtuins, were found to regulate longevity in diverse 
species, ranging from yeast to mammals, stemming 
from fundamental discoveries in Lenny Guarente's lab.  
Sirtuins are also involved in nutrient sensing (and are 
important mediators of the effects of CR), DNA damage 
sensing and responses, genomic stability, metabolic 
diseases, and cancer in mammals [15-24].  Some 
sirtuins seem to act in the same nutrient-sensing 
longevity pathway that is regulated by TOR (target of 
rapamycin) [25].  The sirtuin/TOR pathway extends life 
span by mechanism that overlap with caloric restriction 
(CR) [25].  Accordingly, in 2003, it was demonstrated 
that knocking down TOR in C. elegans more than 
doubles the life span [26].  Likewise, in Drosophila, 
genetic inhibition of the TOR pathway both upstream 
and downstream of TOR extends life span [27].   
Similarly, inhibition of TORC1 signaling in yeast 
extends life span [28, 29]. 
 
Thus, genetic studies have now firmly established that 
aging is regulated by specific genes conserved from 
yeast to mice [23, 30-34]. 
 
Independently of discoveries of AP genes in model 
organisms, research in cellular senescence yielded 
complementary results.  Cellular senescence is now 
widely recognized as an essential tumor suppressor 
mechanisms, and is not a decline due to cellular 
degeneration.  In contrast, the senescence response is an 
active process caused by activation of both DNA-
damage responses (DDR) and mitogen-activated 
pathways.  Senescent fibroblasts acquire phenotypes 
that include hyper-secretion of inflammatory cytokines 
and other tissue-altering molecules and hypertrophic 
morphologies [35-42]. Senescent cells can alter the 
behavior of neighboring cells [35], and may drive aging 
and age-related diseases [43].  Cellular senescence can 
be prevented by knocking out cell cycle inhibitors such 
as p53, pRb, p21 and p16 [44-48].  This disabling of 
cell cycle brakes (and thus immortalization) can occur 
as a consequence of molecular damage and subsequent 
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inhibits cell cycle progression.  Consistent with cellular 
senescence being tumor suppressive, activation of 
growth-promoting pathways such as Ras, Raf, MEK 
and PI-3K leads to senescence [49-51].  Inhibition of 
mTOR decelerates cellular senescence [42]. 
 
Finally, the same signaling pathways (for example, the 
PI-3K pathway) that are involved in cancer are also 
involved in cellular and organismal aging.  Therefore, 
progress in cancer research fosters progress in aging 
research [52-57].  Certain ‘anticancer drugs’ are 
potential ‘anti-aging drugs’, and -- vice versa -- 
inhibition of aging pathways are a strategy to prevent 
cancer [58].   
 
The discovery of telomerase in 1987 [59] lead to an 
understanding of how telomere attrition causes a DNA 
damage response (DDR), culminating in cell cycle 
arrest and cellular senescence [46, 60-62].  Recent 
findings show that expression of telomerase can extend 
lifespan in mice, providing the mice carry extra copies 
of the p53, p16 and Arf tumor suppressor genes, which 
renders them cancer-resistant [63].   
 
Thus, aging is regulated by signaling networks 
encompassing nutrient-sensing, and mitogen-activated, 
stress-responsive and DDR signaling pathways.   
Furthermore, CR modulates portions of the same 
signaling networks.  These networks were conserved 
during evolution and includes genes that are 
antagonistically pleiotropic: they drive growth and 




Of great interest and excitement, aging now appears to 
be regulated at least in part by signal-transduction 
pathways that can be manipulated pharmacologically.   
Prototype anti-aging drugs are available now to treat 
age-related diseases, and are predicted to slow aging 
processes.  Modulators of sirtuins have been discovered 
[64] that mimic CR and mitigate certain age-related 
diseases [65-67].  The TOR pathway is another target.  
Ironically, TOR itself was discovered as target of 
rapamycin in yeast [68] (Sirolimus or Rapamune), a 
clinically available drug that is tolerated even when 
taken in high doses for several years.  Rapamycin has 
potential as a therapy for most of not all age-related 
diseases [69-71], and metformin, an anti-diabetic drug 
and activator of AMPK, which acts in the TOR pathway 
retards aging and extends lifespan in mice [72].    
 
Thus, recent paradigm shifts in aging research has put 
signaling pathways  (growth-promoting pathways, DNA 
damage responses, sirtuins) at front stage, has 
established that aging can be regulated and can be 
inhibited pharmacologically.   
 
At this opportune time, Aging (Impact Journal on Aging 
or Impact Aging) is launched.  This journal  embraces 
the new gerontology.  Recent breakthrough in 
gerontology is due to an integration of different 
disciplines, such as genetics and development in model 
organisms, signal transduction and cell cycle control, 
cancer cell biology and DNA damage responses, 
pharmacology, and the pathogenesis of many age-
related diseases.  The journal will focus on signal 
transduction pathways (IGF- and insulin-activated, 
mitogen-activated and stress-activated pathways, DNA-
damage response, FOXO, Sirtuins, PI-3K, AMPK, 
mTOR) in health and disease.  Topics include cellular 
and molecular biology, cell metabolism, cellular 
senescence, autophagy, oncogenes and tumor sup-
pressor genes, carcinogenesis, stem cells, pharmacology 
and anti-aging agents, animal models, and of course 
age-related diseases such as cancer, Parkinson’s disease, 
type II diabetes, atherosclerosis, macular-degeneration, 
which are deadly manifestations of aging.  The journal 
will also embrace articles that address both the 
possibilities and the limits of the new science of aging.  
Of course, the possibility that the diseases of aging can 
be delayed or treated by drugs that affect the overall 
aging process, thus potentially extending healthy 
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